A Phase 3 interventional study of Ticagrelor and Clopidogrel in Acute Coronary Syndrome and Percutaneous Coronary Intervention, sponsored by AstraZeneca. Completed at 94 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 18th largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 3, and was the 3rd registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
Fu Wai Hospital, Beijing, China · Sites in China
Ages 18+
Shanghai Tong Ren Hospital · Sites in China
Ages 75+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 38
First in 2006; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 801 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 120 across the 67 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
36 studies in Acute Coronary Syndrome by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 8 (23%) have results posted.
Among the 36 studies in Acute Coronary Syndrome by AstraZeneca, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2011, is one of 5 in phase 3, and was the 10th registered.
AstraZeneca’s Acute Coronary Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 36 in Acute Coronary Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese patients with acute coronary syndrome and a planned percutaneous coronary intervention (PCI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ticagrelor (AZD6140)
Drug: Ticagrelor · Drug: Acetylsalicylic acid ASA
Clopidogrel
Drug: Clopidogrel · Drug: Acetylsalicylic acid ASA
90 mg, oral dose twice daily
Also known as: AZD6140
75 mg, oral dose once daily
Also known as: Plavix
Low Dose ASA
Major Bleeding
Time to first occurrence of any major bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.
Time frame: Ongoing up to12 months
Major Adverse Cardiac Events (MACE)
Time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.
Time frame: Ongoing up to 12 months
Major and Minor Bleeding
Time to first occurrence of any major or minor bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.
Time frame: Ongoing up to12 months
Composite of All-cause Mortality, MI or Stroke
Time to first occurrence of any event from the composite of death from any causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.
Time frame: Ongoing up to 12 months
In total, 817 patients were enrolled from 3 countries (Japan, South Korea and Taiwan). Of the randomised patients, most patients were Japanese (723 \[90.3%\]). The first patient was enrolled on 28 February 2010 and the last patient completed the study on 31 July 2012.
| Milestone | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| Started | 401 | 400 |
| Received randomized treatment | 387 | 380 |
| Completed | 335 | 337 |
| Not completed | 66 | 63 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 65 | 63 |
Time to first occurrence of any major bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.
| Percent probability | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| Major Bleeding | 11.2 | 8.4 |
Time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.
| Percent probability | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| Major Adverse Cardiac Events (MACE) | 10.2 | 8.1 |
Time to first occurrence of any major or minor bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.
| Percent probability | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| Major and Minor Bleeding | 26.8 | 16.2 |
Time to first occurrence of any event from the composite of death from any causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.
| Percent probability | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| Composite of All-cause Mortality, MI or Stroke | 10.5 | 8.1 |
Collected over Approximately 6 months to 1 year.. Non-serious events are listed at a 1.8% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor (AZD6140) | — | 92/387 (23.8%) | 327/387 (84.5%) |
| Clopidogrel | — | 112/380 (29.5%) | 337/380 (88.7%) |
| Event | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| Coronary artery stenosisCardiac disorders | 36/387 | 47/380 |
| In-stent coronary artery restenosisInjury, poisoning and procedural complications | 11/387 | 10/380 |
| Angina pectorisCardiac disorders | 5/387 | 9/380 |
| Coronary artery restenosisInjury, poisoning and procedural complications | 6/387 | 8/380 |
| Angina unstableCardiac disorders | 4/387 | 5/380 |
| Thrombosis in deviceGeneral disorders | 2/387 | 4/380 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/387 | 4/380 |
| Acute myocardial infarctionCardiac disorders | 4/387 | 2/380 |
| Cerebral infarctionNervous system disorders | 4/387 | 2/380 |
| Myocardial ischaemiaCardiac disorders | 2/387 | 3/380 |
| Event | Ticagrelor (AZD6140) | Clopidogrel |
|---|---|---|
| NasopharyngitisInfections and infestations | 55/387 | 59/380 |
| ConstipationGastrointestinal disorders | 59/387 | 55/380 |
| HeadacheNervous system disorders | 33/387 | 57/380 |
| InsomniaPsychiatric disorders | 58/387 | 49/380 |
| PyrexiaGeneral disorders | 56/387 | 51/380 |
| Back painMusculoskeletal and connective tissue disorders | 44/387 | 46/380 |
| Myocardial infarcionCardiac disorders | 35/387 | 23/380 |
| VomitingGastrointestinal disorders | 21/387 | 27/380 |
| HypertensionVascular disorders | 23/387 | 27/380 |
| NauseaGastrointestinal disorders | 21/387 | 26/380 |
One discontinued patient (due to withdrawal of consent) in Ticagrelor (AZD6140) group did not agree to disclose any data. Thus the number of baseline participants in Ticagrelor (AZD6140) group is 400 instead of 401 that is the number of participants who started the first period.
| Age, Continuous(Years) | Ticagrelor (AZD6140) | Clopidogrel | Total |
|---|---|---|---|
| Mean | 67 ± 12 | 66 ± 11 | 67 ± 11 |
| Sex: Female, Male(Participants) | Ticagrelor (AZD6140) | Clopidogrel | Total |
|---|---|---|---|
| Female | 95 | 93 | 188 |
| Male | 305 | 307 | 612 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor (AZD6140) | Clopidogrel | Total |
|---|---|---|---|
| Chinese | 16 | 19 | 35 |
| Japanese | 361 | 360 | 721 |
| Korean | 23 | 21 | 44 |
The record gives a start of Feb 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 10 months after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor